Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea

Sohn, Woon Mok; Lee, Oh Young; Lee, Sang Pyo; Lee, Kang Nyeong; Jun, Dae Won; Lee, Hang Lak; Yoon, Byung Chul; Choi, Ho Soon; Sim, Jongsung; Jang, Kiseok

doi:10.3109/00365521.2013.857712

Cited by 58 publications

(71 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher concentrations of CGRP are inhibitory for the immediate SP evoked vasodilation but are also facilitating SP evoked plasma protein extravasation. Although speculative, this interaction could be responsible for the symptom variability that occurs in chronic pain conditions characterized by neurogenic inflammation such as complex regional pain syndrome or irritable bowel syndrome (Sohn et al, 2014).…”

Section: Resultsmentioning

confidence: 99%

Interaction of calcitonin gene related peptide (CGRP) and substance P (SP) in human skin

et al. 2016

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Interaction of calcitonin gene related peptide (CGRP) and substance P (SP) in human skin

et al. 2016

View full text Add to dashboard Cite

“…Substance P–containing enteroendocrine cells are overexpressed in colonoscopic mucosal biopsies from patients with IBS-D compared to controls (29); however, another recent study failed to show increased mucosal concentration of substance P in IBS compared to healthy controls (30). …”

Section: New Classes Of Drugsmentioning

confidence: 99%

Novel therapeutic agents in neurogastroenterology: advances in the past year

Camilleri

2014

Neurogastroenterology Motil

View full text Add to dashboard Cite

Background There have been significant advances in understanding the pathophysiological mechanisms in patients with neurogastroenterological disorders including irritable bowel syndrome (IBS) and functional abdominal pain, functional diarrhea, chronic constipation, gastroparesis, and functional dyspepsia. These advances have led to the development of novel pharmacological therapy of neurogastroenterological disorders. Purpose To review peer‐reviewed articles or prominent preliminary communications presented in the past year regarding medications in development for functional gastrointestinal disorders or gastroparesis. The medications fall into two main categories: first, established classes of medications within established classes, such as 5‐HT3 receptor antagonists and 5‐HT4 receptor agonists, and second, new classes of medications such as a combined μ‐opioid agonist and δ‐antagonist, or a small molecule ghrelin agonist.

show abstract

“…In patients with IBS-D, activation of MCs in the colonic mucosa has been shown to lead to raised levels of gut hormones, vasoactive intestinal peptide and substance P, ultimately causing the diarrheal condition[17]. Since histamine-mediated activation of its cognate H1, H2, H3 and H4 receptors can activate immune-neural signaling in the gut, these receptors represent promising drug targets for treatment of functional gut disorders[18].…”

Section: Introductionmentioning

confidence: 99%

Possible therapeutic role of IgE blockade in irritable bowel syndrome

Magen

Chikovani

2016

WJG

View full text Add to dashboard Cite

Omalizumab is a humanized monoclonal antibody that binds to the high-affinity type-I IgE Fc receptors on mast cells (MCs) and basophils, inhibiting the IgE immune pathway. Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder, and dysregulation of the immune system likely contributes to its etiology and/or symptomatology. Colonic biopsies from patients with IBS demonstrate considerable increase in the number of degranulating MCs releasing histamine in proximity to nerves, and this event may underlie the common IBS symptom of abdominal pain. Pharmacologic control of MC activation and mediator release is a current area of active interest in the field of IBS research. Recently, we and Pearson et al described 2 cases of patients with IBS with diarrhea (IBS-D) showing positive clinical response to omalizumab. In both cases, the female patients had severe, long-lasting IBS-D and achieved an almost complete resolution of IBS symptoms. Both patients were also able to discontinue all IBS medications after commencing the anti-IgE therapy. For both patients, the omalizumab treatment showed a relatively rapid onset of action, resembling the efficacy observed in and previously reported for patients with chronic spontaneous urticaria. In this Editorial, we discuss the possible biological mechanisms that may underlie the clinical efficacy of omalizumab in IBS. We suggest that there is a need for a well-designed prospective study to investigate the therapeutic effects of anti-IgE in IBS.

show abstract

Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea

Abstract: Mast cells are activated leading to the raised levels of substance P & VIP in IBS-D patients. However, the correlation between mast cells and levels of substance P & VIP differs according to gender.

Cited by 58 publications

References 39 publications

Interaction of calcitonin gene related peptide (CGRP) and substance P (SP) in human skin

Interaction of calcitonin gene related peptide (CGRP) and substance P (SP) in human skin

Novel therapeutic agents in neurogastroenterology: advances in the past year

Possible therapeutic role of IgE blockade in irritable bowel syndrome

Contact Info

Product

Resources

About